Related Experiment Videos
A multicenter phase 3 trial of lobeline sulfate for smoking cessation
Elbert D Glover1, Jessica M Rath, Eva Sharma
1Department of Public and Community Health, Center for Health Behavior Research, University of Maryland, College Park School of Public Health, College Park, MD eglover1@umd.edu, USA.
Objective:
To evaluate the safety and efficacy of sublingual lobeline sulfate for smoking cessation.
Methods:
A multicenter (3 sites), double-blind, parallel, placebo-controlled, phase 3 smoking cessation trial of sublingual formulation of lobeline sulfate. A total of 750 smokers (250 per site) were randomized to either treatment (lobeline sulfate) or placebo with individual smoking cessation counseling lasting up to approximately 10 minutes.
Results:
Efficacy revealed no statistical significance (P = 0.62) for lobeline sulfate as a smoking cessation aid.
Conclusion:
Sublingual formulation of lobeline sulfate does not appear to be an effective smoking cessation aid.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Clinical Trials: Overview
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
COPD: Management Using Bronchodilators and Corticosteroids